Company Performance Metrics
- Paul Wegener: President
Epitome Pharmaceuticals identifies, develops and licenses promising medications and technologies. Investigation is conducted by reading the scientific literature, discussing anomalies and questions with leaders in their fields, and by statistical reanalysis of published data. Once a remedy has been identified and intellectual property rights
secured, they proceed to advance the development of the medication. They clarify regulatory issues through close cooperation with regulatory agencies. Based on their research and the prospects for a specific medication, they may file an IND and initiate Phase I or Phase II trials.
Ultimately, Epitome Pharmaceuticals seeks to license its intellectual property to a partner (or partners) with the resources and capabilities to complete clinical trials, secure regulatory approval and bring a product to market most effectively.
